First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

被引：19

作者：

Roohullah, Aflah

Ganju, Vinod

Zhang, Faming

Zhang, Lei

Yu, Ting

Wilkinson, Kate

Cooper, Adam

de Souza, Paul

机构：

[1] South Western Sydney LHD, Liverpool, Australia

[2] Peninsula & Southeast Oncol, Frankston, Vic, Australia

[3] HanX Biopharmaceut Inc, Hangzhou, VA, Peoples R China

[4] Sydney Southwest Private Hosp, Liverpool, NSW, Australia

[5] St George Private Hosp, Liverpool, NSW, Australia

[6] St George Private Hosp, Kogarah, NSW, Australia

[7] Univ Western Sydney, Sch Med, Sydney, NSW, Australia

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.2517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2517

引用

页数：2